» Articles » PMID: 38461202

Right Ventricular Dyssynchrony for the Prediction of Prognosis in Patients with Systemic Lupus Erythematosus-aaociated Pulmonary Arterial Hypertension: a Study with Two-dimensional Speckle Tracking

Overview
Publisher Springer
Specialty Radiology
Date 2024 Mar 9
PMID 38461202
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary arterial hypertension (PAH) is a common complication of systemic lupus erythematosus (SLE), and PAH can cause right ventricle (RV) remodel and dyssynchrony. The aim of this study was to explore the value of RV dyssynchrony in predicting adverse clinical events in patients with systemic lupus erythematosus-aaociated pulmonary arterial hypertension (SLE-PAH) using two-dimensional speckle tracking echocardiography (2D-STE). A total of 53 patients with SLE-PAH were enrolled in this study. The dyssynchrony of the RV (RV-SD6) was evaluated by 2D-STE. The clinical data of all participants were collected, and routine cardiac function parameters were measured by two-dimensional echocardiography, and analyzed for their correlation with RV-SD6. The predictive value of RV-SD6 in clinical adverse event was evaluated. RV-SD6 was negatively correlated with RV-FLS, RV-FAC, and TAPSE (r = - 0.788, r = - 0.363 and r = - 0.325, respectively, all P < 0.01), while the correlation with RV-FLS was the strongest. linear regression analysis showed that RV-FLS was an independent risk factor for RV-SD6 (β = - 1.40, 95% CI - 1.65 ~ - 1.14, P < 0.001). Cox regression analysis showed that RV-SD6 was a predictor with clinical adverse events (HR = 1.03, 95% CI 1 ~ 1.06, P < 0.05). RV-SD6 was highly discriminative in predicting clinical adverse events (AUC = 0.764), at a cutoff of 51.10 ms with a sensitivity of 83.3% and specificity of 68.3%. RV-FLS was negatively correlated with RV-SD6 and was an independent risk factor for it. RV-SD6 can serve as an indicator for predicting the occurrence of adverse clinical events in SLE-PAH patients, with high sensitivity and specificity.

References
1.
Fanouriakis A, Tziolos N, Bertsias G, Boumpas D . Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2020; 80(1):14-25. DOI: 10.1136/annrheumdis-2020-218272. View

2.
Wang H, Wang Q, Tian Z, Guo X, Lai J, Li M . Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension. Heart Lung Circ. 2018; 28(11):1655-1663. DOI: 10.1016/j.hlc.2018.09.002. View

3.
Tian J, Zhang D, Yao X, Huang Y, Lu Q . Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2022; 82(3):351-356. PMC: 9933169. DOI: 10.1136/ard-2022-223035. View

4.
Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z . Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019; 53(2). DOI: 10.1183/13993003.00081-2018. View

5.
Inampudi C, Tedford R, Hemnes A, Hansmann G, Bogaard H, Koestenberger M . Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension. Cardiovasc Diagn Ther. 2020; 10(5):1659-1674. PMC: 7666956. DOI: 10.21037/cdt-20-348. View